Actemra - Biological Therapy for Rheumatoid Arthritis (RA)
Key Data:
Drug (Brand / Generic)
Actemra (tocilizumab)
Company / Licensee
Roche
Therapy Class
Biological response modifier
Product Description
Anti-IL-6 monoclonal antibody
Current Indication
Treatment of RA and sJIA
Market Sector
Musculo-skeletal disorders (anti-inflammatories)
Development Status
Approved in Europe and Japan, pre-registered in the US
